MarketPulse

lunsekimig

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Hurdles in Asthma and Sinus Disease

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.
SNYchronic rhinosinusitis with nasal polypsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Goals in Asthma, Nasal Polyps

Sanofi's lunsekimig met primary endpoints in Phase 2 asthma and nasal polyps trials but failed in atopic dermatitis, advancing respiratory programs with favorable safety.
SNYatopic dermatitisimmunology